Momenta Pharmaceuticals Announces Acceptance of a Clinical

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Momenta Pharmaceuticals Announces Acceptance of a Clinical Trial Application in Europe for M923, a Biosimilar Version of Humira(R)

CAMBRIDGE, Mass., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA ), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the acceptance by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a Clinical Trial Application (CTA) to initiate a clinical trial for M923, a biosimilar version of Humira ® (adalimumab), in its collaboration with Baxter International's biopharmaceutical business. Acceptance of the CTA triggers two milestones under the Baxter collaboration with an aggregate payment of $12 million. Momenta expects to receive the payment in December 2014.

"The European CTA acceptance for M923, our biosimilar version of Humira, represents a significant achievement by Momenta and Baxter in using the biosimilar regulatory pathway in an effort to expand patient choice," said Craig A. Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals. "We look forward to the initiation of the clinical study in first quarter of 2015."

Momenta is using its innovative technology to create a strong pipeline of biosimilars and potentially interchangeable biologics – a completely new segment of the biologics market. Momenta and Baxter have an ongoing collaboration for the worldwide development and commercialization of several biosimilar candidates at various stages of development, including M923 and M834.

About M923, a biosimilar version of Humira ® (adalimumab)
M923 is a biosimilar version of Humira® (adalimumab) developed in collaboration with Baxter. The largest selling therapeutic on the market today, Humira is a transformative therapy for patients with autoimmune/inflammatory diseases. Humira is used to treat many conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis.

About Momenta's biosimilars program
Momenta is applying its complex systems analysis platform to obtain thorough analysis of its biosimilars in relation to the branded biologic. Current biosimilars are being developed and commercialized with an understanding that some aspects of the drug may be different from that of its brand name counterpart. These differences may lead to uncertainty as to how well the biosimilar can replicate the therapeutic effects of its branded counterpart and provide the same safety profile. Momenta is striving to remove that uncertainty and any qualitative product differences by creating thoroughly characterized products that are indistinguishable from the brand name drug.

About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural and functional analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

To receive additional information about Momenta, please visit the website at www.momentapharma.com , which does not form a part of this press release. The company's logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Forward Looking Statements
Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about the Company's anticipated initiation of a European clinical trial, expected receipt or timing of milestone payments in its development programs with Baxter, contributions to expanding affordable patient options, future achievements and related value-creation in the Company's antibody research and development programs and product opportunities. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "hope," "target," "project," "goals," "potential," "predict," "might," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Momenta from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Momenta is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 Media Relations: Karen Sharma MacDougall Biomedical Communications 1-781-235-3060

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fall Pest Risks Linger as Mild Weather Extends Threat

Updated Category News Views 104

A cold snap is not a magic off switch for mosquitoes, ticks, or rodents, and that is the sober point behind the National Pest Management Association's fall and winter 2026 Public Health Pest Index. The group is flagging conditions, not predicting that every household in a named city will face an infestation or illness. Still, mild temperatures, rain, flooding, and plenty...

Continue Reading
Commodity Rout Tests a Market Already Short on Nerve

Updated Category News Views 56

Some weeks the tape merely wobbles; this one started throwing furniture. By midday Wednesday, traders were staring at sharp declines in gold, silver, crude and copper while the major equity benchmarks remained underwater for the week. That is an unpleasant combination. When growth-sensitive commodities and the usual hard-asset hiding places are all getting sold,...

Continue Reading
CVRx Lawsuit Deadline Follows a Brutal 59.76% Plunge

Updated Category News Views 160

A 59.76% one-day wipeout has a way of stripping the varnish off every upbeat corporate story. For CVRx investors, the hard fact is that the shares fell $3.55 to close at $2.39 on August 7, 2026, after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That kind of disclosure does not merely dent confidence; it forces...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 63

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
Norfolk Southern's 200-Year Campaign Meets a Hard Market

Updated Category News Views 111

Two centuries of railroad history can stir the blood, but it does not move a single carload by itself. Norfolk Southern has opened its 200-year railroading celebration with the GeneratioNS campaign, a three-locomotive NS 200 commemorative series, and plans for public events across its network. For a railroad with deep roots and very modern operational pressures, this is...

Continue Reading
Why Lear’s PACE Award Matters Beyond Seat Warmers Today

Updated Category News Views 102

Seat foam and wiring seldom make investors sit upright, yet Lear has managed to turn that unglamorous corner of the vehicle into something worth watching. The company’s Modular Thermal Comfort Systems just won a 2026 Automotive News PACE Award, a respected supplier-industry nod for innovation and business performance. Awards alone do not pay anybody’s bills, and I...

Continue Reading
Common Tiger Bets $499 on Better Outdoor Seating Design

Updated Category News Views 59

A chair that refuses to slump into the camping aisle is Common Tiger's whole argument, and frankly it is a smarter argument than another flimsy fold-up contraption pretending comfort is optional. The Los Angeles, female-founded and women-owned brand is launching with one product, The Daymaker, after four years of development. That is a long runway for a debut chair, which...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 49

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
Frosty Animatronics Put Nostalgia on Lowe's Shelves

Updated Category News Views 142

A moving corncob pipe is not anybody's idea of a macroeconomic signal, yet holiday aisles are built on precisely these little jolts of recognition. Gemmy has teamed with Warner Bros. Discovery Global Consumer Products to place a new animated Frosty the Snowman collection exclusively at Lowe's for the 2026 holiday season. It is cheerful retail business, not earthshaking...

Continue Reading
CHN Energy's Indonesia Record Deserves a Hard Look

Updated Category News Views 50

Twenty years of boots sinking into swamp mud tells a sturdier story than a polished anniversary slogan. CHN Energy says it entered Indonesia's energy market two decades ago and has since built an operating presence around reliable electricity, local training and community work. In a country scattered across thousands of islands, dependable power is not some decorative...

Continue Reading

Top 5 Most Recently Viewed Articles

Arasan Chip Systems Unveils Advanced eUSB2 Solutions for IoT

Updated Category News Views 300

Arasan's Innovative USB2 Solutions Now Available Arasan Chip Systems, a recognized leader in semiconductor intellectual property for mobile and automotive systems on chips (SoCs), has announced the launch of its new Embedded USB2 (eUSB2) IP Core. This cutting-edge technology aims to empower a wide range of electronic devices with efficient connectivity options. Targeting...

Continue Reading
Class Action Filed Against MongoDB: Key Insights and Impacts

Updated Category News Views 98

Overview of the Class Action Lawsuit Against MongoDB Pomerantz LLP has recently brought attention to a significant legal issue concerning MongoDB, Inc. (NASDAQ: MDB). The law firm has filed a class action lawsuit that raises serious questions about the company's compliance with securities laws and the potential consequences for investors. Allegations Explained This...

Continue Reading
Rycor LLC's Strategic Push in Commercial Heating Solutions

Updated Category News Views 136

Expanding Horizons: Rycor LLC Enters Commercial Market RYCOR LLC, well-known as the Northeast's authority in energy-efficient residential mini-splits, is broadening its horizons to embrace the commercial heating and cooling sector. This strategic move represents a significant enhancement in their service offerings, targeting multi-family housing developments, office...

Continue Reading
Successful Charity Ride Brings Community Together for a Cause

Updated Category News Views 148

Second Annual Solstice Century Ride Makes a Big Impact During the longest day of the year, fifty-two enthusiastic riders took on a 100-mile challenge as they participated in the second annual Solstice Century Ride. The event, held at the picturesque Whalon Lake Forest Preserve, proved to be more than just a cycling challenge; it became a powerful avenue for community...

Continue Reading
QuickBooks' Intelligent AI Tool Revolutionizes Business Insights

Updated Category News Views 126

Revolutionizing Business Insights with Intelligent AI In today's fast-paced business environment, understanding how to leverage technology for better decision-making is crucial. Enter QuickBooks' Intelligent AI Dashboard Agent, a powerful tool that has been recognized by industry experts as the best all-in-one solution for real-time business insights in 2025. This...

Continue Reading